NO941915L - Madikament for nervebeskyttelse - Google Patents

Madikament for nervebeskyttelse

Info

Publication number
NO941915L
NO941915L NO941915A NO941915A NO941915L NO 941915 L NO941915 L NO 941915L NO 941915 A NO941915 A NO 941915A NO 941915 A NO941915 A NO 941915A NO 941915 L NO941915 L NO 941915L
Authority
NO
Norway
Prior art keywords
active ingredient
drug containing
medicine
brain
drug
Prior art date
Application number
NO941915A
Other languages
English (en)
Other versions
NO941915D0 (no
Inventor
Yasufumi Shirasaki
Hitoshi Yamaguchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO941915D0 publication Critical patent/NO941915D0/no
Publication of NO941915L publication Critical patent/NO941915L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Et medikament som inneholder en kalmodulininhibitor som en aktiv bestanddel er beskrevet. Dette medikament kan anvendes for å undertrykke nervecelledød, særlig nervecelledød i hjernen som f.eks. skyldes cerebral ischemi. Et medikament som inneholder en forbindelse som er i stand til å inhibere binding av kalmodulin til et celle- skjelettprotein som en aktiv bestanddel og et medikament som inneholder en forbindelse som undertrykker nedbrytningen av et celleskjelettprotein som en aktiv bestanddel er også be- skrevet. Disse medikamenter kan anvendes i behandlingen og forebygging av forskjellige sykdommer i hjernen og ettersyk- dommer derav, så vel som for å forhindre tilbakefall av disse sykdommer.
NO941915A 1993-05-25 1994-05-24 Madikament for nervebeskyttelse NO941915L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12293393 1993-05-25

Publications (2)

Publication Number Publication Date
NO941915D0 NO941915D0 (no) 1994-05-24
NO941915L true NO941915L (no) 1994-11-28

Family

ID=14848208

Family Applications (2)

Application Number Title Priority Date Filing Date
NO941915A NO941915L (no) 1993-05-25 1994-05-24 Madikament for nervebeskyttelse
NO993627A NO993627D0 (no) 1993-05-25 1999-07-26 Anvendelse av en forbindelse for fremstilling av et legemiddel

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO993627A NO993627D0 (no) 1993-05-25 1999-07-26 Anvendelse av en forbindelse for fremstilling av et legemiddel

Country Status (10)

Country Link
US (2) US5661150A (no)
EP (1) EP0627219A1 (no)
CN (1) CN1100301A (no)
AU (2) AU684270B2 (no)
CA (1) CA2124284C (no)
FI (1) FI942400A (no)
NO (2) NO941915L (no)
PH (1) PH31213A (no)
RU (1) RU2135162C1 (no)
TW (1) TW309427B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0792879B1 (en) * 1994-11-14 2001-02-28 Daiichi Pharmaceutical Co., Ltd. Process for preparing 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate
CA2188816C (en) * 1996-04-23 2009-09-22 Takeda Chemical Industries, Ltd. Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
DE19820224A1 (de) * 1998-05-06 1999-12-09 Markus Schott Bindungspartner und Verfahren zur kompetitiven Hemmung der Bindung zwischen NEF-Protein und Calmodulin, sowie Mittel und Verwendung bei HIV-Erkrankungen
EP1087775B1 (en) 1998-06-17 2005-08-17 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6105582A (en) * 1998-07-28 2000-08-22 Pranevicius; Osvaldas Cerebral blood outflow maintenance during intracranial hypertension
WO2002010768A2 (en) * 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
GB2377635B (en) * 2001-04-17 2005-10-19 Hoffmann La Roche Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
WO2007062862A2 (en) * 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
WO2024018245A1 (en) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en) 2023-01-20 2024-07-25 Institut National de la Santé et de la Recherche Médicale Autophagy activators for the treatment of rhabdomyolysis

Also Published As

Publication number Publication date
PH31213A (en) 1998-05-05
CN1100301A (zh) 1995-03-22
FI942400A0 (fi) 1994-05-24
TW309427B (no) 1997-07-01
FI942400A (fi) 1994-11-26
AU5837298A (en) 1998-05-21
RU94017849A (ru) 1997-05-27
US5661150A (en) 1997-08-26
US5837706A (en) 1998-11-17
AU6333194A (en) 1994-12-01
EP0627219A1 (en) 1994-12-07
NO941915D0 (no) 1994-05-24
NO993627D0 (no) 1999-07-26
CA2124284A1 (en) 1994-11-26
AU684270B2 (en) 1997-12-11
CA2124284C (en) 2002-10-01
NO993627L (no) 1994-11-28
RU2135162C1 (ru) 1999-08-27

Similar Documents

Publication Publication Date Title
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
DK65293A (da) Fremgangsmåde til administrering af taxol
NO941915L (no) Madikament for nervebeskyttelse
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
EP0616032A3 (en) Preventive or therapeutic agents for Alzheimer's disease, a seven-test method, and human tau protein kinase.
DK0603649T3 (da) Substituerede 4-phenyl-pyridoner og 4-phenyl-2-alkoxypyridiner som HMG-CoA-reduktase-inhibitorer
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
EP0620004A4 (en) MEDICAL COMPOSITION.
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
Lee et al. Poison ivy, oak, and sumac dermatitis.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
AU1956399A (en) Composition containing propargylamine for enhancing cancer therapy
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
Melzack et al. Diflunisal (1000 mg single dose) versus acetaminophen (650 mg) and placebo for the relief of post-episiotomy pain.
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
IE35419L (en) Pharmaceutical composition containing cyclobenzaprine
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
EP0523013A3 (en) Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases